Ozette, a technology-driven life sciences startup engineering a transformative leap in cell discovery and annotation of the human immune system, today announced its $26MM Series A funding, led by Madrona Ventures. Other participating investors include Cercano Management (formerly Vulcan Capital), M12, Microsoft’s venture fund, Alexandria Venture Investments, OCV Partners and Duke University.
We’re proud to announce Ozette co-founder and Scientific Advisor Dr. Raphael Gotardo’s role as principal investigator for The Chan Zuckerberg Initiative project to decode single-cell CITE-seq data, co-led by associate professor at the Fred Hutchinson Cancer Center Dr. Evan Newell.
Business Insider features Ozette as one of the 21 most promising healthtech startups, along with Solv, Truepill and WELL Health, as ranked by VCs. Haomiao Huang at Kleiner Perkins nominated Ozette, noting that, “Ozette’s AI-driven solution has been succeeding in turning these high-dimensional problems in immune profiling into solvable and usable building blocks for drug development and scientific research.” Click through to Business Insider to read the full list, available with subscription.
Hear Ozette co-founder and CTO Greg Finak discuss how we leverage machine learning in next generation high-resolution immune profiling.
Fred Hutch spin out Ozette, raises 6M in seed funding to develop its AI powered immune monitoring platform in a round led by Madrona Venture Group. Ozette’s raise will fund team growth and technology development.